Back to search results

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced or Metastatic Solid Tumors · Non Small Cell Lung Cancer · NSCLC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Elise Johnson)
    Contact: Principal Investigator (Frank Yung-Chin Tsai, MD)

  • Yale Cancer Center, New Haven, Connecticut, United States

    Contact: Study coordinator (Alicia Appiah-Chin)
    Contact: Principal Investigator (Patricia LoRusso, DO)

  • Mass General Cancer Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Kyndall Hailey)
    Contact: Principal Investigator (Aparna Parikh, MD)

  • Providence Cancer Institute Franz Clinic, Portland, Oregon, United States

    Contact: Study coordinator (Annie Long)
    Contact: Principal Investigator (Rachel Sanborn, MD)

  • University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Rebekah Caza)
    Contact: Principal Investigator (Jordan Berlin, MD)

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Julia Moore)
    Contact: Principal Investigator (Funda Meric-Bernstam, MD)

  • NEXT Houston, Houston, Texas, United States

    Contact: Study coordinator (Emma Morales)
    Contact: Principal Investigator (Jennifer Segar, MD)

  • Next Oncology, Irving, Texas, United States

    Contact: Study coordinator (Selena Morales)
    Contact: Principal Investigator (Shiraj Sen, MD, PhD)

  • NEXT Oncology, San Antonio, Texas, United States

    Contact: Study coordinator (Jordan Georg)
    Contact: Principal Investigator (David Sommerhalder, MD)

  • Next Oncology, Fairfax, Virginia, United States

    Contact: Study coordinator (Maybelle De La Rosa)
    Contact: Principal Investigator (Alex Spira, MD,PhD,FACP)
Study leads

  • Joseph Paul Eder, MD

    Study Chair

    Incendia Therapeutics

View source on ClinicalTrials.gov(opens in a new tab)